With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Halozyme makes 2 billion euro buyout offer for drug developer Evotec November 14, 2024 Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends ...